Search research articles
Contact Us
Filters
Showing results (41-50 of 123) with videos related to
Page
of 13
Sort By:
Investigational New Drugs
|
April 11, 2023
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors
Anastasios Stathis, Anthony W Tolcher, Judy S Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 24, 2007
First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors
Pamela N Munster, Carolyn D Britten, Monica Mita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2008
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin
Anthony W Tolcher, Alain Mita, Lionel D Lewis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 29, 2017
First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors
Kyriakos P Papadopoulos, Larry Gluck, Lainie P Martin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 5, 2020
A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
Monica M Mita, Patricia M LoRusso, Kyriakos P Papadopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 7, 2004
A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer
Anthony W Tolcher, John Kuhn, Garry Schwartz, et al.
Cancer Chemotherapy and Pharmacology
|
October 3, 2015
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study
Anthony W Tolcher, Patricia LoRusso, Jennifer Arzt, et al.
Investigational New Drugs
|
March 8, 2014
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors
Colin D Weekes, Muralidhar Beeram, Anthony W Tolcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2014
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors
Kyriakos P Papadopoulos, Josep Tabernero, Ben Markman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2002
A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies
Eric K Rowinsky, Jinee Rizzo, Leonel Ochoa, et al.
Page
of 13
Search research articles
Search
Showing results (41-50 of 123) with videos related to
Sort By:
Page
of 13
Investigational New Drugs
|
April 11, 2023
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors
Anastasios Stathis, Anthony W Tolcher, Judy S Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 24, 2007
First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors
Pamela N Munster, Carolyn D Britten, Monica Mita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2008
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin
Anthony W Tolcher, Alain Mita, Lionel D Lewis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 29, 2017
First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors
Kyriakos P Papadopoulos, Larry Gluck, Lainie P Martin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 5, 2020
A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
Monica M Mita, Patricia M LoRusso, Kyriakos P Papadopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 7, 2004
A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer
Anthony W Tolcher, John Kuhn, Garry Schwartz, et al.
Cancer Chemotherapy and Pharmacology
|
October 3, 2015
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study
Anthony W Tolcher, Patricia LoRusso, Jennifer Arzt, et al.
Investigational New Drugs
|
March 8, 2014
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors
Colin D Weekes, Muralidhar Beeram, Anthony W Tolcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2014
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors
Kyriakos P Papadopoulos, Josep Tabernero, Ben Markman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2002
A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies
Eric K Rowinsky, Jinee Rizzo, Leonel Ochoa, et al.
Page
of 13